scholarly journals Neurotensin Receptor-1 Expression in Human Prostate Cancer: A Pilot Study on Primary Tumors and Lymph Node Metastases

2019 ◽  
Vol 20 (7) ◽  
pp. 1721 ◽  
Author(s):  
Clément Morgat ◽  
Adrien Chastel ◽  
Vincent Molinie ◽  
Romain Schollhammer ◽  
Gaétan Macgrogan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Nodes ◽  
Distant Metastases ◽  
Human Prostate ◽  
Normal Prostate ◽  
Tissue Samples ◽  
Primary Tumors ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph ◽  
Prostate Cancers

Neurotensin and its high-affinity receptor, NTR1, are involved in the growth of various tumors. Few data are available regarding NTR1 expression in normal and tumoral human prostate tissue samples. NTR1 expression was assessed using immunohistochemistry in 12 normal prostate tissues, 11 benign prostatic hyperplasia (BPH), 44 prostate cancers, and 15 related metastatic lymph nodes (one per patient, when available). NTR1-staining was negative in normal prostate and BPH samples. NTR1 was overexpressed in four out of 44 (9.1%) primary tumors. There was no clear association between NTR1 overexpression and age, PSA-values, Gleason score, pT-status, nodal-status, or margin. NTR1 was expressed at a high level of five out of 15 (33.3%) metastatic lymph nodes. NTR1 overexpression was thus more frequent in metastatic lymph nodes than in primary tumors (p = 0.038). In this limited series of samples, NTR1 overexpression was observed in few primary prostate cancers. Upregulation was more frequent in related lymph nodes. The presence of this target in metastatic lymph nodes may open new perspectives for imaging and radionuclide therapy of prostate cancer. Factors driving NTR1 expression in primary prostate cancer and in nodal and distant metastases still need to be characterized.

scholarly journals HERV-K Gag RNA and Protein Levels Are Elevated in Malignant Regions of the Prostate in Males with Prostate Cancer

Viruses ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 449
Author(s):  
Simin D. Rezaei ◽  
Joshua A. Hayward ◽  
Sam Norden ◽  
John Pedersen ◽  
John Mills ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Lines ◽  
Endogenous Retrovirus ◽  
Human Endogenous Retrovirus ◽  
Normal Prostate ◽  
Tissue Samples ◽  
Gag Protein ◽  
Protein Levels ◽  
Prostate Epithelial Cells ◽  
Prostate Cancers

Heightened expression of human endogenous retrovirus (HERV) sequences has been associated with a range of malignancies, including prostate cancer, suggesting that they may serve as useful diagnostic or prognostic cancer biomarkers. We analysed the expression of HERV-K (Gag and Env/Np9 regions), HERV-E 4.1 (Pol and Env regions), HERV-H (Pol) and HERV-W (Gag) sequences in prostate cancer cells lines and normal prostate epithelial cells using qRT-PCR. HERV expression was also analysed in matched malignant and benign prostate tissue samples from men with prostate cancer (n = 27, median age 65.2 years (range 47–70)) and compared to prostate cancer-free male controls (n = 11). Prostate cancer epithelial cell lines exhibited a signature of HERV RNA overexpression, with all HERVs analysed, except HERV-E Pol, showing heightened expression in at least two, but more commonly all, cell lines analysed. Analysis of primary prostate material indicated increased expression of HERV-E Pol but decreased expression of HERV-E Env in both malignant and benign regions of the prostate in men with prostate cancer as compared to those without. Expression of HERV-K Gag was significantly higher in malignant regions of the prostate in men with prostate cancer as compared to matched benign regions and prostate cancer-free men (p < 0.001 for both), with 85.2% of prostate cancers donors showing malignancy-associated upregulation of HERV-K Gag RNA. HERV-K Gag protein was detected in 12/18 (66.7%) malignant tissues using immunohistochemistry, but only 1/18 (5.6%) benign tissue sections. Heightened expression of HERV-K Gag RNA and protein appears to be a sensitive and specific biomarker of prostate malignancy in this cohort of men with prostate carcinoma, supporting its potential utility as a non-invasive, adjunct clinical biomarker.

Deoxyribonucleic Acid Ploidy of Core Biopsies and Metastatic Lymph Nodes of Prostate Cancer Patients: Impact On Time to Progression

1993 ◽  
Vol 150 (2 Part 1) ◽  
pp. 400-406 ◽  
Author(s):  
Dies van den Ouden ◽  
Bernhard Tribukait ◽  
Jan H.M. Blom ◽  
Sophie D. Fossa ◽  
Karl H. Kurth ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Deoxyribonucleic Acid ◽  
Time To Progression ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph

High Expression of sLex Associated with Poor Survival in Argentinian Colorectal Cancer Patients

2014 ◽  
Vol 29 (1) ◽  
pp. e30-e39 ◽  
Author(s):  
Ariel Zwenger ◽  
Martin Rabassa ◽  
Sandra Demichelis ◽  
Gabriel Grossman ◽  
Amada Segal-Eiras ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Normal Mucosa ◽  
Poor Survival ◽  
Primary Tumors ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph ◽  
Colorectal Cancer Patients

Aim Colorectal cancer (CRC) is one of the most prevalent malignancies in Argentina with 11,043 new cases and 6,596 deaths estimated to have occurred in 2008. The present study was developed to clarify the differential expression of MUC1, MUC2, sLex, and sLea in colorectal cancer patients and their relationship with survival and clinical and histological features. Methods Ninety primary tumor samples and 43 metastatic lymph nodes from CRC patients were studied; follow-up was documented. Twenty-six adenoma and 68 histological normal mucosa specimens were analyzed. An immunohistochemical approach was applied and statistical analysis was performed. Results In tumor samples, MUC1, sLea, and sLex were highly expressed (94%, 67%, and 91%, respectively); also, we found a significantly increased expression of the 3 antigens in primary tumors and metastatic lymph nodes compared with normal mucosa and adenomas. MUC2 was expressed in 52% of both normal mucosa and CRC samples; this reactivity significantly decreased in metastatic lymph nodes (p<0.05). A multiple comparison analysis showed that MUC1 and sLex discriminated among 3 groups: normal, adenoma, and CRC tissues. The increase of sLex expression showed an association with recurrence, and survival analysis showed that a high sLex staining was significantly associated with a poor survival. By multivariate analysis MUC1 inmunoreactivity correlated positively and significantly with tumor size, while MUC2 expression showed the opposite correlation. Conclusions The correlation of sLex overexpression in primary tumors and metastatic lymph nodes, the discrimination among the normal, adenoma, and CRC groups based on sLex expression, as well as its association with recurrence and survival, all suggest a prognostic role of sLex in Argentinian CRC patients.

Cellular Proliferative Fraction of Metastatic Lymph Nodes Predicts Survival in Stage D1 (TxN+MO) Prostate Cancer

1996 ◽  
Vol 155 (5) ◽  
pp. 1674-1677 ◽  
Author(s):  
Michael L. Cher ◽  
Robert A. Stephenson ◽  
Brent C. James ◽  
Peter R. Carroll
Keyword(s):  
Prostate Cancer ◽  
Lymph Nodes ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph

Expression of PI3K/p-AKT/p-mTOR in gastric carcinoma and its correlation with clinicopathologic characteristics.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 73-73
Author(s):  
Ying Jieer ◽  
Xu Qi ◽  
Liu Bixia ◽  
Cheng Xiangdong
Keyword(s):  
Gastric Cancer ◽  
Lymph Nodes ◽  
Expression Patterns ◽  
Clinicopathological Characteristics ◽  
Mtor Pathway ◽  
Clinicopathologic Characteristics ◽  
Primary Tumors ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph ◽  
Tumor Specificity

73 Background: The objective of this study was to explore the expression patterns of PI3K/p-AKT/p-mTOR in gastric cancer (GC) and its relationship with clinicopathological characteristics and thereby to understand the role of activated PI3K/AKT/mTOR pathway in the initiation and development of gastric cancer. Methods: Envision immunohistochemistry assay was used to examine the expression patterns of PI3K, p-AKT and p-mTOR in primary GC sites, metastatic lymph nodes and peritumoral mucosa among 50 patients who underwent radical gastrectomy for stage I-IV (M0) gastric cancer. Results: The PI3K, p-AKT and p-mTOR showed significantly higher expressions in primary tumor sites and metastatic lymph nodes as compared to that of the peritumoral mucosa. The study of the pathway components and clinicopathological characteristics revealed that p-AKT and p-mTOR expressions were selectively higher in primary tumors with less than 5 cm diameter. The PI3K, p-AKT and p-mTOR positive patients had shorter median survival time as compared to the patients negative for them (42.8 m vs. 57.0 m, 46.8 m vs. 55.9 m, 47.2 m vs. 53.0 m). However, the differences were not statistically significant. Conclusions: Activation of PI3K/AKT/mTOR pathway was associated with the development and prognosis of gastric cancer. The expression of PI3K/p-AKT/p-mTOR was correlated well with tumor specificity in gastric cancer and they might have some potential as promising targets for clinical therapy.

RA07.09: THE EFFICACY OF ASSESSING METASTATIC LYMPH NODES BY COMPUTED TOMOGRAPHY IN ADVANCED ESOPHAGEAL CANCER WITH NEOADJUVANT CHEMOTHERAPY

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 37-37
Author(s):  
Shinya Urakawa ◽  
Tomoki Makino ◽  
Koji Tanaka ◽  
Yasuhiro Miyazaki ◽  
Tsuyoshi Takahashi ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Reduction Rate ◽  
Short Axis ◽  
Advanced Esophageal Cancer ◽  
Primary Tumors ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph

Abstract Background Although various modalities including CT, endoscopy, and positron emission tomography (PET) have been used to predict pathological tumor response (pTR) to neoadjuvant chemotherapy (NACT) or prognosis in esophageal cancer patients, an optimal method of response evaluation remains to be established. Methods A total of 97 non-T4 thoracic esophageal cancer patients who underwent curative surgery after NACT from 2011 to 2014 with both measurable primary tumors (PT) and metastatic lymph nodes (LNs) by CT (≥ 10mm in short axis or ≥ 5mm in short axis with SUV-max ≥ 2.5) were analyzed. Patients with ≥ 50% decrease in size of the PT (two-direction measurement) and ≥ 30% decrease in size of LNs (sum of short diameter based on RECIST criteria) were defined as PT- and LNs-responders, respectively. Results The median reduction rate of PT and LNs were 62.0% (5.5–93.4) and 26.7% (60.9–13.6), respectively. Of 97 patients, 62 (69%) and 45 patients (45%) were classified as PT- and LNs-responders respectively. The concordance rate between CT response of PT and LNs was 66% (P = 0.01). CT response of PT was correlated with pTR (P<0.0001) while CT response of LNs was associated with pT (P = 0.0011), pN(P = 0.0004), and pTR (P < 0.0001). Receiver operating characteristic (ROC) curves demonstrated the highest accuracy (AUC 0.75), sensitivity (88.9%) and specificity (60.9%) at the reduction rate of 53% (P = 0.007) which was approximated to the cutoff value we used. In univariate analysis of recurrence free survival (RFS), pT, pN, pM, CT response of both PT and LNs, and pTR were significantly correlated with RFS. Multivariate analysis further identified CT response of LNs (HR 2.68 P = 0.003) and pTR (HR 2.72 P = 0.022) to be independently associated with RFS. When classified into three groups by histological grade and CT response of LNs [group A (grade2–3/LNs-responders), group B (grade1a-1b/LNs-nonresponders), and group C (others)], 2-year RFS were 83% in the groupA, 59% in groupC and 29% in groupB (P < 0.0001), respectively. Conclusion In locally-advanced esophageal cancer patients with NACT followed by surgery, CT response of PT and LNs significantly correlated with pTR. Especially, CT response of LNs was important to predict prognosis in addition to pTR. Disclosure All authors have declared no conflicts of interest.

Sign in / Sign up

Export Citation Format

Share Document